150 related articles for article (PubMed ID: 37643088)
1. Correction to: Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.
Jpn J Clin Oncol; 2023 Oct; 53(10):1000-1001. PubMed ID: 37643088
[No Abstract] [Full Text] [Related]
2. Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.
Tsuji T; Matsuda S; Takeuchi M; Kawakubo H; Kitagawa Y
Jpn J Clin Oncol; 2023 Jul; 53(8):645-652. PubMed ID: 37282626
[TBL] [Abstract][Full Text] [Related]
3. [Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)].
; ; ;
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(33):2552-2570. PubMed ID: 37650202
[TBL] [Abstract][Full Text] [Related]
4. Current Value of Perioperative Therapies for Resectable or Borderline Resectable Pancreatic Cancer.
Murakami Y; Sakamoto T; Hanaki T; Tokuyasu N; Fujiwara Y
Yonago Acta Med; 2023 May; 66(2):202-207. PubMed ID: 37229366
[TBL] [Abstract][Full Text] [Related]
5. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial).
van der Sluis PC; Ruurda JP; van der Horst S; Verhage RJ; Besselink MG; Prins MJ; Haverkamp L; Schippers C; Rinkes IH; Joore HC; Ten Kate FJ; Koffijberg H; Kroese CC; van Leeuwen MS; Lolkema MP; Reerink O; Schipper ME; Steenhagen E; Vleggaar FP; Voest EE; Siersema PD; van Hillegersberg R
Trials; 2012 Nov; 13():230. PubMed ID: 23199187
[TBL] [Abstract][Full Text] [Related]
6. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma.
Iyengar S; Nevala-Plagemann C; Garrido-Laguna I
Ther Adv Med Oncol; 2021; 13():17588359211045861. PubMed ID: 34552668
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemotherapy for resectable thoracic esophageal cancer.
Malthaner R; Fenlon D
Cochrane Database Syst Rev; 2001; (1):CD001556. PubMed ID: 11279723
[TBL] [Abstract][Full Text] [Related]
8. Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
Kim Y; Yamamoto S; Kato K
Cancer Manag Res; 2023; 15():399-406. PubMed ID: 37197006
[TBL] [Abstract][Full Text] [Related]
9. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
Matsuda S; Takeuchi H; Kawakubo H; Ando N; Kitagawa Y
Ann Thorac Cardiovasc Surg; 2016 Oct; 22(5):275-283. PubMed ID: 27384595
[TBL] [Abstract][Full Text] [Related]
10. Surgical treatment of esophageal cancer in the era of multimodality management.
Borggreve AS; Kingma BF; Domrachev SA; Koshkin MA; Ruurda JP; van Hillegersberg R; Takeda FR; Goense L
Ann N Y Acad Sci; 2018 Dec; 1434(1):192-209. PubMed ID: 29761863
[TBL] [Abstract][Full Text] [Related]
11. The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer.
Zacherl J
Dig Dis; 2014; 32(1-2):171-5. PubMed ID: 24603404
[TBL] [Abstract][Full Text] [Related]
12. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Esophageal Cancer Patients: A Systematic Review and Meta-Analysis.
Xiao X; Hong HG; Zeng X; Yang YS; Luan SY; Li Y; Chen LQ; Yuan Y
World J Surg; 2020 Dec; 44(12):4161-4174. PubMed ID: 32761259
[TBL] [Abstract][Full Text] [Related]
14. [Neoadjuvant therapy for resectable esophageal cancer].
Hejna M; Raderer M
Z Gastroenterol; 2005 Oct; 43(10):1141-7. PubMed ID: 16220454
[TBL] [Abstract][Full Text] [Related]
15. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
[TBL] [Abstract][Full Text] [Related]
16. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival.
Sinn M; Bahra M; Denecke T; Travis S; Pelzer U; Riess H
World J Gastrointest Oncol; 2016 Mar; 8(3):248-57. PubMed ID: 26989460
[TBL] [Abstract][Full Text] [Related]
17. Esophageal Cancer: New Insights into a Heterogenous Disease.
Krug S; Michl P
Digestion; 2017; 95(4):253-261. PubMed ID: 28384630
[TBL] [Abstract][Full Text] [Related]
18. Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review.
Mukherji R; Alqahtani A; Yin C; Caso R; Noel MS; Khaitan PG
J Thorac Dis; 2023 Jun; 15(6):3466-3487. PubMed ID: 37426147
[TBL] [Abstract][Full Text] [Related]
19. Early intervention of the perioperative multidisciplinary team approach decreases the adverse events during neoadjuvant chemotherapy for esophageal cancer patients.
Shirakawa Y; Noma K; Maeda N; Tanabe S; Sakurama K; Sonoyama-Hanaoka A; Yoshitomi A; Kohno-Yamanaka R; Soga Y; Fujiwara T
Esophagus; 2021 Oct; 18(4):797-805. PubMed ID: 33999305
[TBL] [Abstract][Full Text] [Related]
20. The role of neoadjuvant therapy in surgically resectable esophageal cancer.
Swisher SG; Holmes EC; Hunt KK; Doty JE; Zinner MJ; McFadden DW
Arch Surg; 1996 Aug; 131(8):819-24; discussion 824-5. PubMed ID: 8712904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
